Oramed's subsidiary, @OravaxMedical’s oral VLP vaccine, target's not one but three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, making the oral COVID-19 vaccine in development, potentially more effective against the #omicron variant. $ORMP
konori
>>116
Oramed's subsidiary, @OravaxMedical’s oral VLP vaccine, target's not one but three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, making the oral COVID-19 vaccine in development, potentially more effective against the #omicron variant. $ORMP